PRTK Paratek Pharmaceuticals, Inc. Stock Quote

PRTK [NASD]

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	6.80%	Shs Outstand	46.66M	Perf Week	-7.28%
Market Cap	258.98M	Forward P/E	-	EPS next Y	-0.02	Insider Trans	-2.03%	Shs Float	42.89M	Perf Month	-24.83%
Income	-87.30M	PEG	-	EPS next Q	0.32	Inst Own	55.60%	Short Float	9.64%	Perf Quarter	-29.56%
Sales	55.40M	P/S	4.67	EPS this Y	44.40%	Inst Trans	0.17%	Short Ratio	7.33	Perf Half Y	-17.72%
Book/sh	-2.55	P/B	-	EPS next Y	97.30%	ROA	-45.80%	Target Price	-	Perf Year	12.53%
Cash/sh	2.19	P/C	2.50	EPS next 5Y	-	ROE	95.70%	52W Range	4.11 - 11.23	Perf YTD	-12.46%
Dividend	-	P/FCF	-	EPS past 5Y	12.60%	ROI	-52.50%	52W High	-51.22%	Beta	1.54
Dividend %	-	Quick Ratio	5.60	Sales past 5Y	-	Gross Margin	82.10%	52W Low	33.33%	ATR	0.42
Employees	196	Current Ratio	6.20	Sales Q/Q	107.60%	Oper. Margin	-	RSI (14)	26.70	Volatility	6.48% 5.02%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	40.70%	Profit Margin	-	Rel Volume	0.54	Prev Close	5.52
Shortable	Yes	LT Debt/Eq	-	Earnings	May 17 BMO	Payout	-	Avg Volume	563.95K	Price	5.48
Recom	1.50	SMA20	-15.65%	SMA50	-29.92%	SMA200	-21.94%	Volume	306,766	Change	-0.72%

Apr-23-21

Upgrade

WBB Securities

Speculative Buy → Buy

$6 → $10

Mar-02-21

Initiated

Jefferies

Buy

$15

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$19 → $22

Jan-08-20

Initiated

WBB Securities

Speculative Buy

Jan-02-19

Initiated

Canaccord Genuity

Buy

$14

Nov-23-18

Reiterated

H.C. Wainwright

Buy

$55 → $22

Aug-27-18

Initiated

BofA/Merrill

Neutral

$13

Mar-02-18

Downgrade

Raymond James

Strong Buy → Outperform

Oct-24-17

Initiated

Guggenheim

Buy

$44

Jul-18-17

Reiterated

H.C. Wainwright

Buy

$36 → $43

May-19-17

Initiated

Raymond James

Strong Buy

Apr-11-17

Reiterated

H.C. Wainwright

Buy

$33 → $36

Apr-04-17

Reiterated

Wedbush

Outperform

$30 → $34

Apr-04-17

Initiated

Wedbush

Outperform

$30

Oct-27-16

Resumed

Leerink Partners

Outperform

$23

Jun-17-16

Reiterated

H.C. Wainwright

Buy

$31 → $34

May-13-16

Initiated

Robert W. Baird

Outperform

$30

Mar-30-16

Resumed

Cantor Fitzgerald

Buy

$27

Feb-29-16

Initiated

H.C. Wainwright

Buy

$32

Jul-22-15

Initiated

Gabelli & Co

Buy

$34

Jun-29-21 08:00AM	Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million GlobeNewswire
Jun-16-21 12:29PM	Why Paratek Pharmaceuticals Stock Is Sinking Today Motley Fool -12.12%
09:33AM	Paratek Launches Mid-Stage NTM Program With Nuzyra, Second Procurement Under BARDA Pact Expected In 2H 2022 Benzinga
Jun-14-21 08:00AM	Paratek Appoints Minnie Baylor-Henry to Companys Board of Directors GlobeNewswire
Jun-11-21 06:54AM	Is Paratek Pharmaceuticals' (NASDAQ:PRTK) 151% Share Price Increase Well Justified? Simply Wall St.
Jun-10-21 08:00AM	Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus GlobeNewswire +7.90%
Jun-09-21 10:25AM	3 Strong Buy Stocks Riding a Momentum Wave TipRanks
Jun-08-21 11:07AM	Crestone Joins Antimicrobials Working Group PR Newswire
Jun-01-21 06:36PM	Why Paratek Pharmaceuticals Crushed the Market Today Motley Fool +19.59%
04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:45AM	Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) GlobeNewswire
May-26-21 04:17PM	Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-17-21 10:00PM	Paratek Pharmaceuticals (PRTK) Q1 2021 Earnings Call Transcript Motley Fool
08:45AM	Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:30AM	Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement GlobeNewswire
06:45AM	Paratek Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-10-21 04:05PM	Paratek Pharmaceuticals to Report First Quarter 2021 Financial Results on May 17, 2021 GlobeNewswire
May-03-21 04:01PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-12-21 01:59PM	Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last? Zacks
07:12AM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Is Breakeven Near? Simply Wall St.
Apr-01-21 04:01PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-01-21 04:01PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-25-21 12:01AM	Paratek Pharmaceuticals (PRTK) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:01PM	Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million GlobeNewswire
02:30PM	Paratek Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 04:01PM	Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-17-21 04:01PM	Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 GlobeNewswire
Feb-10-21 12:06AM	Some Analysts Just Cut Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Estimates Simply Wall St.
Feb-08-21 08:00AM	Paratek Announces Expansion of NUZYRA® Launch into the Community Setting GlobeNewswire +5.73%
Feb-01-21 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-06-21 08:00AM	Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference GlobeNewswire
Jan-04-21 05:00PM	Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group GlobeNewswire
Dec-25-20 04:07AM	How Much Did Paratek Pharmaceuticals'(NASDAQ:PRTK) Shareholders Earn From Share Price Movements Over The Last Five Years? Simply Wall St.
Dec-10-20 09:40PM	Is PRTK A Good Stock To Buy Now? Insider Monkey
Dec-01-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-12-20 04:01PM	Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-05-20 06:35PM	Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Paratek Pharmaceuticals Announces Third Quarter 2020 Total Revenue of $13.7 Million GlobeNewswire
02:30PM	Paratek Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-29-20 12:35PM	Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-27-20 08:00AM	Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-26-20 02:52PM	What Kind Of Investors Own Most Of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)? Simply Wall St.
Oct-21-20 08:00AM	Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020 GlobeNewswire
Sep-09-20 04:01PM	Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire +10.98%
09:36AM	Billionaire David Shaw Pours Money Into 3 Strong Buy Stocks TipRanks
Sep-01-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-25-20 10:17AM	Market Sentiment Around Loss-Making Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Simply Wall St.
Aug-10-20 08:45AM	Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:12AM	Recap: Paratek Pharmaceuticals Q2 Earnings Benzinga
07:30AM	Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million GlobeNewswire
Aug-05-20 04:01PM	Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences GlobeNewswire
Aug-03-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
12:31PM	Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-28-20 04:01PM	Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020 GlobeNewswire
12:33PM	Will Paratek Pharmaceuticals (PRTK) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-05-20 03:05PM	Should You Avoid Paratek Pharmaceuticals Inc (PRTK)? Insider Monkey
Jun-12-20 04:46PM	Edited Transcript of PRTK earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-29-20 08:30AM	Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders GlobeNewswire
May-28-20 08:00AM	Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-11-20 04:05PM	Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference GlobeNewswire
07:55AM	Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:14AM	Paratek Pharmaceuticals: Q1 Earnings Insights Benzinga
06:30AM	Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million GlobeNewswire
Apr-30-20 08:00AM	Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020 GlobeNewswire -7.47%
Apr-28-20 12:14PM	Will Paratek Pharmaceuticals Continue to Surge Higher? Zacks
Apr-14-20 12:26PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-02-20 08:00AM	Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA (omadacycline) GlobeNewswire
Apr-01-20 08:00AM	Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA (omadacycline) GlobeNewswire -5.71%
Mar-14-20 10:55AM	Paratek Pharmaceuticals, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Mar-10-20 05:12PM	Edited Transcript of PRTK earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
04:01PM	Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA (omadacycline) GlobeNewswire
Mar-02-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-27-20 11:50AM	Paratek Pharmaceuticals, Inc. Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Feb-26-20 08:00AM	Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire +20.00%
Feb-25-20 05:35PM	Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million GlobeNewswire
Feb-24-20 07:00AM	Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region GlobeNewswire
Feb-17-20 01:36PM	Is Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) A Volatile Stock? Simply Wall St.
Feb-13-20 04:01PM	Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire
Jan-14-20 03:12PM	Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020 Zacks -5.33%
Dec-20-19 08:38AM	Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock? Zacks
Dec-19-19 09:33PM	Why this King of Prussia biopharma's stock rose 32% Thursday American City Business Journals +32.20%
08:53AM	Paratek's stock rockets on government contract MarketWatch
07:52AM	The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 05:12PM	Paratek Awarded BARDA Project BioShield Contract for NUZYRA® GlobeNewswire
Dec-13-19 03:06PM	Is Paratek Pharmaceuticals Inc (PRTK) Going to Burn These Hedge Funds? Insider Monkey +5.48%
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-02-19 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-19 11:02AM	Penny Stocks to Buy Using Technical Analysis for December 2019 Investopedia
Nov-28-19 06:59PM	Edited Transcript of PRTK earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 12:14PM	Did Changing Sentiment Drive Paratek Pharmaceuticals's (NASDAQ:PRTK) Share Price Down A Painful 79%? Simply Wall St. -8.19%
Nov-12-19 05:15PM	Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019 GlobeNewswire
Nov-05-19 10:31AM	Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks +24.53%
Nov-04-19 04:05PM	Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019 GlobeNewswire
Nov-01-19 04:05PM	Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:38AM	The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 04:05PM	Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections GlobeNewswire

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Woodrow Adam	President & Chief Commercial	Jun 04	Sale	9.70	17,182	166,665	474,796	Jun 08 07:34 PM
Haskel William M.	CLO, General Counsel & Sec.	Jun 04	Sale	9.70	7,561	73,342	357,092	Jun 08 07:32 PM
Brenner Randall B.	Chief Development & Regulatory	Jun 04	Sale	9.70	9,978	96,787	268,940	Jun 08 07:30 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Jun 04	Sale	9.70	34,364	333,331	879,312	Jun 08 07:28 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Dec 14	Sale	6.71	26,063	174,883	546,517	Dec 15 07:47 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 14	Sale	6.71	8,760	58,780	128,782	Dec 15 07:50 PM
Haskel William M.	CLO, General Counsel & Sec.	Dec 14	Sale	6.71	6,842	45,910	203,267	Dec 15 07:52 PM
Woodrow Adam	President & Chief Commercial	Dec 14	Sale	6.71	12,855	86,257	271,273	Dec 15 07:54 PM
Loh Evan	CEO	Dec 14	Sale	6.71	26,415	177,245	600,559	Dec 15 07:56 PM
Loh Evan	CEO	Dec 11	Sale	6.95	18,585	129,166	626,974	Dec 15 07:56 PM
Woodrow Adam	President & Chief Commercial	Dec 11	Sale	6.95	9,045	62,863	284,128	Dec 15 07:54 PM
Haskel William M.	CLO, General Counsel & Sec.	Dec 11	Sale	6.95	4,814	33,457	210,109	Dec 15 07:52 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 11	Sale	6.95	6,164	42,840	137,542	Dec 15 07:50 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Dec 11	Sale	6.95	18,337	127,442	572,580	Dec 15 07:47 PM
Loh Evan	CEO	Nov 13	Sale	5.93	20,928	124,103	645,559	Nov 16 06:36 PM
Brenner Randall B.	Chief Development & Regulatory	Nov 13	Sale	5.93	8,357	49,557	143,706	Nov 16 06:33 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Nov 13	Sale	5.93	26,250	155,662	590,917	Nov 16 06:30 PM
Haskel William M.	CLO, General Counsel & Sec.	Nov 13	Sale	5.93	6,892	40,870	214,923	Nov 16 06:28 PM
Woodrow Adam	President & Chief Commercial	Nov 13	Sale	5.93	15,000	88,950	293,173	Nov 16 06:23 PM
Loh Evan	CEO	Oct 29	Option Exercise	4.30	39,479	169,760	591,487	Nov 02 04:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience